Loading...

Harrow Health, Inc. 11.875% Senior Notes due 2027

HROWMNASDAQ
Healthcare
Medical - Pharmaceuticals
$26.58
$0.00(0.00%)

Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Stock Overview

Explore Harrow Health, Inc. 11.875% Senior Notes due 2027’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.4/100

Key Financials

Market Cap1.1B
P/E Ratio-54.47
EPS (TTM)N/A
ROE-0.28%
Fundamental Analysis

AI Price Forecasts

1 Week$26.03
1 Month$26.57
3 Months$26.84
1 Year Target$26.48

HROWM Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $26.48.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -54.47 and a market capitalization of 1.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for HROWMStats details for HROWM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for HROWMAnalyst Recommendations details for HROWM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

CEO

Mark L. Baum

Employees

217

Headquarters

Nashville

Founded

2022

Frequently Asked Questions

;